Champion swimmer Archie Goodburn, 24, who is battling a rare and inoperable form of brain cancer, has issued a passionate plea for the UK government to increase its support for individuals affected by this devastating condition. Goodburn, a former representative for his country, argues that the current level of funding and treatment options is woefully inadequate, especially in light of his own experience with the illness.
A Life-Changing Diagnosis
Goodburn’s journey took a dramatic turn two years ago when he began experiencing alarming symptoms during training. These included a loss of strength, numbness on his left side, and overwhelming feelings of fear and nausea. “It felt like my consciousness was being pulled away from me,” he recounted. Just months before the Paris Olympics qualifiers, he missed qualifying by mere tenths of a second, only to later discover that three oligodendrogliomas—rare tumours comprising about 3% of all brain cancer cases—were the cause.
Fortunately, Goodburn was recently given access to Vorasidenib, an innovative treatment that has allowed him to return to competition at the upcoming Commonwealth Games in Glasgow. This breakthrough has postponed the need for chemotherapy and radiotherapy, which could have severely affected his cognitive abilities and hindered his studies in chemical engineering. However, Goodburn remains critical of the slow pace of drug development, lamenting the fact that only one new drug has emerged in the past two decades. “Vorasidenib only bought me four years, according to the trials. I need more. And I’m not going to stop [campaigning] until my last breath,” he asserted.
The Funding Crisis
Brain cancer remains the leading cause of cancer-related deaths for both children and adults under 40. Shockingly, since 2002, the condition has received a mere 1% of the national cancer research budget in the UK. Goodburn highlights a significant “translational gap” that exists between groundbreaking research and the funding needed for clinical trials. This gap has been termed the “valley of death” by the all-party parliamentary group on brain tumours, which points to a risk-averse funding system as a significant barrier to progress.
Even when funding is available, regulatory hurdles often impede its application. The government’s previous pledge of £40 million for brain cancer research has not been fully realised, with only a fraction of that amount being allocated to frontline scientists over recent years. Goodburn, along with the Brain Cancer Justice campaign, is urging the government to release the remaining funds and establish a dedicated brain cancer lead to oversee advancements in research and treatment options. They are also advocating for increased genome sequencing for patients upon diagnosis, which could expand access to clinical trials, and the introduction of a “right to try” policy for potentially life-saving treatments.
Government Response
The Department of Health and Social Care has acknowledged the need for enhanced research into brain tumours, stating its commitment to improving patient access to innovative medicines. However, many advocates, including Goodburn, express frustration over the slow pace of change. The standard treatment path for Goodburn’s type of cancer typically involves radiotherapy and chemotherapy, which he would have started last July had he not been able to access Vorasidenib through an expanded access programme. This drug works by inhibiting the proteins that allow his tumours to grow.
Goodburn’s recent achievements in the pool demonstrate the potential of new treatments to transform lives. Shortly after beginning Vorasidenib, he set a new Scottish record in the 50m breaststroke, the event in which he will compete at the Commonwealth Games. “There’s so much space for change. Change is so possible,” he declared with optimism.
Balancing Advocacy and Athletics
As Goodburn prepares for his upcoming competition, he is also gearing up for a significant moment in Westminster. He will be in the viewing room on Monday while MPs debate a petition that he and Brain Cancer Justice have been tirelessly advocating for, gathering signatures to push for better funding and support for brain cancer research. Juggling training with advocacy work has been a challenge, but Goodburn remains resolute. “I campaign, if I’m being completely honest, because of the disparity in care, the lack of funding, but also because I believe that my campaigning can actually make a difference to my own future,” he shared. “In some ways, it’s a treatment of its own.”
Why it Matters
Goodburn’s fight for better support and funding for brain cancer research is not just a personal battle; it is a rallying cry for countless others facing similar challenges. His advocacy shines a light on the systemic issues within the healthcare system that hinder progress and innovation. As he prepares to compete on an international stage, his efforts remind us of the urgent need for increased investment in research to ensure that future generations have access to effective treatments. The outcomes of his campaign could significantly impact not only his future but also the lives of many others affected by this devastating illness.
